argenx SE (NASDAQ:ARGX) Receives Average Recommendation of “Moderate Buy” from Brokerages
argenx SE (NASDAQ:ARGX – Get Free Report) has been assigned an average rating of “Moderate Buy” from the twenty analysts that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation, sixteen have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $550.95.
A number of analysts recently weighed in on ARGX shares. Citigroup cut their target price on shares of argenx from $610.00 to $591.00 and set a “buy” rating on the stock in a research note on Wednesday, November 29th. Raymond James cut their target price on shares of argenx from $600.00 to $580.00 and set a “strong-buy” rating on the stock in a research note on Wednesday, November 29th. HC Wainwright cut their target price on shares of argenx from $595.00 to $582.00 and set a “buy” rating on the stock in a research note on Wednesday, November 29th. TD Cowen upped their price target on argenx from $612.00 to $641.00 and gave the company an “outperform” rating in a report on Tuesday. Finally, Morgan Stanley lowered their price target on argenx from $607.00 to $586.00 and set an “overweight” rating for the company in a report on Thursday, November 30th.
View Our Latest Analysis on ARGX
argenx Price Performance
Shares of NASDAQ:ARGX opened at $461.47 on Thursday. The firm has a market capitalization of $27.26 billion, a PE ratio of -110.93 and a beta of 0.72. The firm’s 50-day moving average is $479.60 and its two-hundred day moving average is $468.44. argenx has a 1 year low of $333.07 and a 1 year high of $550.76.
argenx (NASDAQ:ARGX – Get Free Report) last issued its quarterly earnings results on Tuesday, October 31st. The company reported ($1.25) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.48) by $0.23. The company had revenue of $339.84 million for the quarter, compared to analyst estimates of $310.06 million. argenx had a negative net margin of 22.70% and a negative return on equity of 12.40%. During the same period in the prior year, the firm earned ($4.26) earnings per share. Analysts expect that argenx will post -4.8 EPS for the current fiscal year.
Institutional Investors Weigh In On argenx
Large investors have recently modified their holdings of the stock. Parkside Financial Bank & Trust purchased a new stake in shares of argenx during the third quarter worth approximately $28,000. KB Financial Partners LLC raised its stake in shares of argenx by 112.5% during the first quarter. KB Financial Partners LLC now owns 85 shares of the company’s stock worth $27,000 after purchasing an additional 45 shares during the last quarter. Nkcfo LLC purchased a new stake in shares of argenx during the second quarter worth approximately $37,000. Toronto Dominion Bank purchased a new stake in shares of argenx during the first quarter worth approximately $36,000. Finally, Captrust Financial Advisors raised its position in argenx by 116.7% in the first quarter. Captrust Financial Advisors now owns 143 shares of the company’s stock worth $45,000 after acquiring an additional 77 shares in the last quarter. Hedge funds and other institutional investors own 52.77% of the company’s stock.
argenx Company Profile (Get Free Report
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany, France, Canada, the United Kingdom, and Italy. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, pemphigus foliaceus, chronic inflammatory demyelinating polyneuropathy, bullous pemphigoid, and idiopathic inflammatory myopathy; and ENHANZE SC.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider argenx, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and argenx wasn’t on the list.
While argenx currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.